Logo

CCM

Concord Medical Services Holdings Limited

CCM

Concord Medical Services Holdings Limited • NYSE
$3.91 ▼ -2.01% (-0.08)
Market Cap $569351
52w High $10.77
52w Low $3.60
Dividend Yield 0%
P/E -0.74
Volume 700
Outstanding Shares 145.61K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $100.308M $70.183M $-13.568M -13.526% $-93.3 $-42.042M
Q1-2025 $100.308M ▲ $70.183M ▼ $-13.568M ▲ -13.526% ▲ $-93.3 ▲ $-42.042M ▲
Q4-2024 $82.573M $148.425M $-67.993M -82.342% $-466.8 $-136.925M ▲
Q3-2024 $82.573M ▼ $148.425M ▲ $-67.993M ▲ -82.342% ▼ $-466.8 ▲ $-137.501M ▼
Q2-2024 $109.405M $78.074M $-86.129M -78.725% $-591.6 $-69.165M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $177.389M $6.733B $5.011B $-2.239B
Q1-2025 $177.389M ▼ $6.733B ▲ $5.011B ▼ $-2.239B ▲
Q4-2024 $350.845M $6.726B $5.109B $-2.28B
Q3-2024 $350.845M ▲ $6.726B ▲ $5.109B ▲ $-2.28B ▼
Q2-2024 $326.905M $6.623B $4.702B $-2.139B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-13.568M $0 $0 $0 $0 $0
Q1-2025 $-13.568M ▲ $0 $0 $0 $0 $0
Q4-2024 $-67.993M $0 $0 $0 $0 $0
Q3-2024 $-67.993M ▲ $0 $0 $0 $0 $0
Q2-2024 $-86.129M $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement Concord Medical has been running at a loss for many years, with revenue still very small relative to its cost base. The core medical services have not yet reached a point where they reliably cover direct costs, leading to ongoing negative gross margins. Operating losses are sizable and persistent, and bottom‑line results remain deeply negative. There are no clear signs yet of a sustained turnaround in profitability, which suggests the current business scale is still too small and too costly for the model they are pursuing.

Balance Sheet

Balance Sheet The balance sheet shows a financially stressed profile. Total assets are modest, while debt makes up a large share of the funding, and cash on hand is thin. Shareholder equity has been negative for several years, meaning liabilities exceed assets, a sign of accumulated losses and high leverage. This structure leaves little cushion against setbacks and makes the company highly dependent on lenders and new capital to keep funding operations and expansion.

Cash Flow

Cash Flow The company consistently uses cash rather than generating it. Day‑to‑day operations have been consuming cash each year, indicating that the current hospital and service network is not yet self‑funding. On top of that, heavy spending on new facilities and advanced equipment has pushed free cash flow further into negative territory. This pattern fits a business in an investment and build‑out phase, but it also means continued reliance on outside financing and exposes the firm to funding and liquidity risk if capital becomes harder or more expensive to obtain.

Competitive Edge

Competitive Edge Strategically, Concord Medical is aiming for a differentiated spot in China’s cancer care market by moving from being a service partner to running its own high‑end oncology hospitals. Its long experience operating radiotherapy and imaging centers provides relationships, brand recognition, and a patient funnel. The proton therapy focus, supported by AI tools, positions it in a niche where there are relatively few capable players. International partnerships with top cancer centers enhance credibility and know‑how. However, this is a capital‑intensive, highly regulated field, and large public and private hospitals are strong competitors. Concord’s financial fragility could limit how fast and how broadly it can scale its concept compared with better‑funded rivals.

Innovation and R&D

Innovation and R&D Innovation is the clear bright spot. Concord Medical is investing in advanced cancer treatments, especially proton therapy, and has developed its own AI‑driven planning system to improve precision and efficiency. This proprietary platform, along with a “healing village” hospital concept and an integrated care model, gives the company a distinctive offering in China. Continued progress will depend on proving that these technologies deliver better clinical outcomes and lower costs in practice, and on successfully rolling out similar centers in other major cities. The partnership network with leading global cancer institutions supports ongoing clinical, operational, and technology learning.

Summary

Concord Medical is in the middle of a major strategic shift: from a service provider within other hospitals to an owner‑operator of high‑tech cancer centers built around proton therapy and AI. On the strategic and technological side, the story is attractive—early mover advantages, strong international ties, and a differentiated, comprehensive oncology model. On the financial side, the story is challenging—chronic losses, negative equity, high leverage, and ongoing cash burn driven by heavy investment. The future hinges on whether the new hospitals can scale, fill capacity, and eventually convert this innovative platform into sustainable profits before financial constraints become too tight. Uncertainty is high, and execution and funding risks are central to the outlook.

NEWS

September 26, 2025 · 7:30 AM UTC

Concord Medical Reports Financial Results for the First Half of 2025

Read more